These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24368611)

  • 1. Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon Cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Am J Ther; 2016; 23(3):e720-9. PubMed ID: 24368611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
    Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
    Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
    Iwashyna TJ; Lamont EB
    J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
    Sundararajan V; Mitra N; Jacobson JS; Grann VR; Heitjan DF; Neugut AI
    Ann Intern Med; 2002 Mar; 136(5):349-57. PubMed ID: 11874307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
    Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital lymph node examination rates and survival after resection for colon cancer.
    Wong SL; Ji H; Hollenbeck BK; Morris AM; Baser O; Birkmeyer JD
    JAMA; 2007 Nov; 298(18):2149-54. PubMed ID: 18000198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
    Mack CD; Glynn RJ; Brookhart MA; Carpenter WR; Meyer AM; Sandler RS; Stürmer T
    Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):810-8. PubMed ID: 23296544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice.
    Satkunam N; Wei X; Biagi JJ; Nanji S; Booth CM
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1548-1554. PubMed ID: 27956539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.
    Hanna NN; Onukwugha E; Choti MA; Davidoff AJ; Zuckerman IH; Hsu VD; Mullins CD
    Colorectal Dis; 2012 Jan; 14(1):48-55. PubMed ID: 21689262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.